427 related articles for article (PubMed ID: 31595860)
21. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
[TBL] [Abstract][Full Text] [Related]
23. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
Cochet A; David S; Moodie K; Drummond E; Dutu G; MacManus M; Chua B; Hicks RJ
Cancer Imaging; 2014 Apr; 14(1):13. PubMed ID: 25608599
[TBL] [Abstract][Full Text] [Related]
24. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of efficacy and clinical impact of FDG-PET on patients with suspicion of recurrent cutaneous melanoma].
Borrego Dorado I; Vázquez Albertino R; López Martín J; Alvarez Pérez RM
Rev Esp Med Nucl; 2006 Sep; 25(5):301-11. PubMed ID: 17173776
[TBL] [Abstract][Full Text] [Related]
26. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
[TBL] [Abstract][Full Text] [Related]
27. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
[TBL] [Abstract][Full Text] [Related]
28. Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.
Kirchner J; Sawicki LM; Suntharalingam S; Grueneisen J; Ruhlmann V; Aktas B; Deuschl C; Herrmann K; Antoch G; Forsting M; Umutlu L
PLoS One; 2017; 12(2):e0172553. PubMed ID: 28225831
[TBL] [Abstract][Full Text] [Related]
29.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
30. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
31. Role of
Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
[TBL] [Abstract][Full Text] [Related]
32. Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma.
Povoski SP; Hall NC; Martin EW; Walker MJ
World J Surg Oncol; 2008 Jan; 6():1. PubMed ID: 18186915
[TBL] [Abstract][Full Text] [Related]
33. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
[TBL] [Abstract][Full Text] [Related]
34. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
35. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
37. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
[TBL] [Abstract][Full Text] [Related]
38. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
[TBL] [Abstract][Full Text] [Related]
40. The role of
Angelini A; Ceci F; Castellucci P; Graziani T; Polverari G; Trovarelli G; Palmerini E; Ferrari S; Fanti S; Ruggieri P
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1712-1720. PubMed ID: 28405727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]